Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Hospitals’ efforts to reduce readmissions within 30 days of discharge aren’t going very well, according to the latest numbers from the Centers for Medicare & Medicaid Services.
CVS Health and IBM will use predictive analytics and Watson cognitive computing to transform care management services for patients with chronic disease.
Northwest Medical Center has deployed the latest advanced digital monitoring technology to deliver enhanced safety, care and peace-of-mind to patients for surgical patients. The wireless, wrist-worn device, named the ViSii® Mobile System, continuously tracks patient vital sign data and transmits the information to clinicians on-site or remotely.
Use of wearables and mobile health apps has been growing but a new survey indicates users do not feel that their data are sufficiently secured by manufacturers.
The Department of Health and Human Services (HHS) is doing its part to create an interoperable learning health system by awarding 20 entities $38 million for three grant programs.
The Bipartisan Policy Center is pushing Congress to take all sorts of policy actions to speed new drugs and medical devices to patients who need them sooner rather than later.
BOSTON—People think it can’t be true, but software has been regulated for decades, said Bradley Merrill Thompson, JD, attorney with Epstein, Becker & Green, during a session on regulatory decisions at mHealth + Telehealth 2015.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
